SI Stock Forecast & Price Target

Shoulder Innovations Inc. demonstrated significant growth in the fourth quarter of FY25, with a 58% year-over-year increase in total revenue, reaching $11.8 million. The company’s positive trajectory is further supported by the strong adoption of its implant portfolio among surgeons, evidenced by a 61.4% growth in core-contender surgeon customers, which positions the company for continued success in customer acquisition. Additionally, management's confidence is reflected in their raised sales outlook, anticipating annual sales between $45 million and $46 million, suggesting high revenue potential moving forward.

Shoulder Innovations Inc has reported an adjusted EBITDA loss of $7.5 million, which exceeded previous models by approximately $400,000, indicating operational challenges and potential revenue shortfalls. The company faces significant risks, including slower adoption of its products by new surgeons, lower growth rates in the shoulder market, and higher-than-anticipated operating expenses, which collectively contribute to a projected EBITDA loss of $23.6 million. Additionally, increased selling, general, and administrative expenses, driven by higher headcount and unexpected legal costs, further exacerbate the financial strain facing the company.